Dr. Luskey is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4455 W 117th St
Ste 300
Hawthorne, CA 90250Phone+1 310-645-0444Fax+1 310-978-0379
Education & Training
University of Texas at Austin Dell Medical SchoolResidency, Internal Medicine, 1976 - 1979
University of Texas Southwestern Medical SchoolClass of 1976
Certifications & Licensure
CA State Medical License 1994 - 2026
TX State Medical License 1982 - 2017
SC State Medical License 1995 - 1998- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Clinical Trials
- A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes Start of enrollment: 2013 Mar 01
- A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes Start of enrollment: 2013 May 01
- A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes Start of enrollment: 2013 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- 153 citationsRegulation of synthesis and degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by low density lipoprotein and 25-hydroxycholesterol in UT-1 cellsJerry R. Faust, Kenneth L. Luskey, Daniel J. Chin, Joseph L. Goldstein, Michael S. Brown
Proceedings of the National Academy of Sciences of the United States of America. 1982-09-01 - 58 citationsContinuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 d...Robert R. Henry, Julio Rosenstock, Douglas Logan, Thomas R. Alessi, Kenneth L. Luskey
Journal of Diabetes and Its Complications. 2014-05-01 - 34 citationsRandomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 DiabetesRobert R. Henry, Julio Rosenstock, Douglas Logan, Thomas R. Alessi, Kenneth L. Luskey
Diabetes Care. 2013-09-01
Grant Support
- Amylin Expression In Normal And Diabetic StatesNational Institute Of Diabetes And Digestive And Kidney Diseases1995
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
